Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD7451 |
| Synonyms | |
| Therapy Description |
AZD7451 is a selective pan-TRK inhibitor, which may inhibit growth of TRK overexpressing tumor cells (PMID: 25054037, PMID: 31762816). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD7451 | AZD 7451|AZD-7451 | Trk Receptor Inhibitor (Pan) 33 | AZD7451 is a selective pan-TRK inhibitor, which may inhibit growth of TRK overexpressing tumor cells (PMID: 25054037, PMID: 31762816). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 dec exp NTRK2 dec exp | pulmonary large cell neuroendocrine carcinoma | no benefit | AZD7451 | Preclinical | Actionable | In a preclinical study, AZD7451 treatment did not inhibit proliferation of a lung large-cell neuroendocrine carcinoma cell line with reduced Ntrk1 and Ntrk2 expression level in culture (PMID: 25054037). | 25054037 |
| NTRK2 positive | pulmonary large cell neuroendocrine carcinoma | sensitive | AZD7451 | Preclinical | Actionable | In a preclinical study, AZD7451 treatment inhibited proliferation of a lung large-cell neuroendocrine carcinoma cell line expressing Ntrk2 in culture (PMID: 25054037). | 25054037 |
| NTRK1 fusion | colorectal cancer | sensitive | AZD7451 | Preclinical | Actionable | In a preclinical study, AZD7451 treatment efficiently inhibited proliferation of a colorectal cancer cell line harboring a NTRK1 fusion in culture (PMID: 25054037). | 25054037 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|